Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies - Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TISvopra) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit...

Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting - Recommended Phase 2 dose determined for future JTX-4014 trials - - Introducing the dosing and sequencing strategy for vopratelimab and ipilimumab in ongoing EMERGE Phase 2 trial - CAMBRIDGE,...

Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer - Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE,...

Kuebix Extends Load Matching Service with Emerge Marketplace MAYNARD, Mass. and SCOTTSDALE, Ariz., April 30, 2019 (GLOBE NEWSWIRE) -- Kuebix, creator of the industry’s fastest growing transportation management system (TMS), and Emerge, developer of the first...

Elm Street Technology Announces Acquisition of eMerge and Announces the Launch of 3sixtyfive, a Full-Service Creative and Digital Marketing Agency Strategic Acquisition Will Provide Major Feature Enhancements to the Elevate Technology Platform and Provide Creative and Design Services to its Customers GREENSBORO, N.C. and NEW ORLEANS, Oct. 17,...